Category: Health Science
-
Stocks go green as Deloitte predicts spring rate cut 01-04-23
The TSX bumped 56.43 to 20875.01. TSX Venture moved up 1.11 to 551.18 while the CSE Composite edged higher to 170.32. There was a sense of positivity in the markets after Deloitte Canada predicted BoC would cut rates in the spring and even though H1 will see stagnant growth as a hangover from last years…
-
Optimi Health (OPTI.C) transforming psychedelic treatment and wellness
In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the population aged 15 and older. This growing trend underscores the importance of addressing mental health issues at a societal and policy level, with an emphasis on…
-
VentriPoint Diagnostics (VPT.V): A powerful new AI-powered face in cardiac care
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States, costing approximately $239.9 billion in 2019 alone due to the cost of health care services, medicines, and lost productivity due to death, not to mention the emotional toll on patients and their friends and…
-
InnoCan Pharma’s (CSE: INNO) investment potential in the Pharmaceuticals Sector: A Balanced View
InnoCan Pharma Corporation, trading on the Canadian Securities Exchange under the symbol INNO, FSE: IP4, and OTC: INNPF, is a pharmaceutical technology company that has garnered attention in the investment community. This article evaluates its potential as an investment option in the pharmaceuticals space, considering both its recent achievements and challenges. Business Model and Strategic…
-
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Several years back, Hugh Rogers was in my office talking about his cannabis company. Way back then, the plan was to grow in Germany and be first on the continent, using an old wartime bunker as a ‘safe growing facility’. Those plans morphed quickly as the reality of the cannabis space became clear. The cannabis…
-
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
Perimeter Medical Imaging AI (PINK.V): After 3 years, it’s half-priced, AI-based, and in FDA trials
If you’ve been around here for a while, like going back three years or so ago, you may recall a former client company in Perimeter Medical Imaging (PINK.V). I really loved repping PINK, because sometimes it’s nice to be able to say that you really ARE trying to cure cancer, and make some profit while…
-
Cannabis memory lane: Who’s sticking it out, who’s dead and dying
I was feeling every ounce of my chest cold, the thing everyone apparently has, the one that’s going around, the one that’s not covid but who could tell. I was also standing on a stage at the Richmond Chamber of Commerce awards gala, blinking at stage lights and peaking over the shoulders of some very…
-
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…